A new publication in Frontiers in Neurology, stemming from an international research collaboration with CSL, validates the significance of Brainomix's follow-up infarct volume (FIV) automated imaging biomarkers to predict clinical outcomes after acute ischemic stroke (AIS).

The study, Automatically Quantified Follow-Up Imaging Biomarkers Predict Clinical Outcomes After Acute Ischemic Stroke, was a collaboration between Brainomix, CSL and leading stroke researchers from Oxford University, the Mayo Clinic, Beaumont Hospital in Dublin, and centers across the Czech Republic.

"CSL is proud to champion research which can improve and optimize clinical trial design. Working with partners like Brainomix, we are contributing to a better understanding of selection and endpoint markers in acute ischemic stroke, which in turn can improve the development of treatment for patients," Moshe Vardi, MD, Vice President, R&D Therapeutics Area Co-Lead at CSL.

"Brainomix has the most extensive and well validated suite of AI biomarkers in the field of stroke. It was a pleasure to collaborate on this important research, showing how Brainomix's quantitative AI imaging can improve patient characterization and outcome assessment in stroke clinical trials," Waleed Brinjikji, MD, Professor of Radiology & Neurosurgery, Mayo Clinic Rochester.

"We are proud to publish this activity from our partnership with CSL, which further highlights the valuable role played by Brainomix AI imaging biomarkers in clinical trials," Dr George Harston, Chief Medical & Innovation Officer at Brainomix.

A full copy of the study can be found here.